Akari Therapeutics Enters Material Definitive Agreement
Ticker: AKTX · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1541157
Sentiment: neutral
Topics: material-definitive-agreement, corporate-actions
Related Tickers: AKTX
TL;DR
Akari Therapeutics just signed a big deal, filing an 8-K today.
AI Summary
Akari Therapeutics Plc entered into a material definitive agreement on September 19, 2025. The company, formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC, is incorporated in England and Wales and is in the pharmaceutical preparations industry. The filing also lists financial statements and exhibits.
Why It Matters
This filing indicates a significant new contract or partnership for Akari Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- Celsus Therapeutics Plc (company) — Former Company Name
- Morria Biopharmaceuticals PLC (company) — Former Company Name
- September 19, 2025 (date) — Date of earliest event reported
- 20250919 (date) — Conformed period of report
FAQ
What is the nature of the material definitive agreement entered into by Akari Therapeutics Plc?
The filing states that Akari Therapeutics Plc entered into a material definitive agreement on September 19, 2025, but the specific details of the agreement are not provided in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 19, 2025.
What were Akari Therapeutics Plc's former company names?
Akari Therapeutics Plc was formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC.
In which jurisdiction is Akari Therapeutics Plc incorporated?
Akari Therapeutics Plc is incorporated in England and Wales.
What is Akari Therapeutics Plc's Standard Industrial Classification code?
Akari Therapeutics Plc's Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 2,077 words · 8 min read · ~7 pages · Grade level 15.6 · Accepted 2025-09-25 17:00:30
Key Financial Figures
- $0.0001 — Market LLC Ordinary Shares, par value $0.0001 per share* N/A The Nasdaq Stock Mar
- $0.7 m — ") in the aggregate principal amount of $0.7 million, which were originally scheduled
- $2.04 — Shares"), of the Company at a price of $2.04 per ADS (representing $0.00102 per unde
- $0.00102 — a price of $2.04 per ADS (representing $0.00102 per underlying Ordinary Share) and the
- $0.81 — ersion price of the April 2023 Notes to $0.81 per ADS (representing $0.000405 per und
- $0.000405 — 23 Notes to $0.81 per ADS (representing $0.000405 per underlying Ordinary Share) and perm
- $81,700 — e holders an aggregate of approximately $81,700, representing all interest accrued on t
- $3 million — gregate purchase price of approximately $3 million. The aggregate principal amount of the
- $3.8 million — st 2025 Notes issuable is approximately $3.8 million. Further, the Company agreed to amend t
- $625,000 — the August 2025 Notes Offering, issuing $625,000 aggregate principal amount of August 20
- $500,000 — otes for an aggregate purchase price of $500,000 . Following this closing, the Company
- $3.5 million — the Company has issued an aggregate of $3.5 million principal amount of August 2025 Notes.
Filing Documents
- form8-k.htm (8-K) — 59KB
- ex10-1.htm (EX-10.1) — 25KB
- 0001493152-25-014962.txt ( ) — 297KB
- aktx-20250919.xsd (EX-101.SCH) — 4KB
- aktx-20250919_def.xml (EX-101.DEF) — 26KB
- aktx-20250919_lab.xml (EX-101.LAB) — 36KB
- aktx-20250919_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: September 25, 2025 By: /s/ Torsten Hombeck Name: Torsten Hombeck Title: Chief Financial Officer